

INDEX*

I.	MJ Egorin, DA Van Echo, SJ Tipping, EA Olman, MY Whitacre, BW Thompson, J Aisner <i>Pharmacokinetics and dosage reduction of cis-diammine (1,1-cyclobutanedi-carboxylato) platinum in patients with impaired renal function.</i> Cancer Res 1984; 44: 5432-5438. [269]	1
II.	WE Evans, WR Crom, M Abromowitch, R Dodge, AT Look, WP Bowman, SL George, C-H Pui <i>Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect.</i> N Engl J Med 1986; 314: 471-477. [213]	11
III.	JH Rodman, M Abromowitch, JA Sinkule, FA Hayes, GK Rivera, WE Evans <i>Clinical pharmacodynamics of continuous infusion teniposide: Systemic exposure as a determinant of response in a phase I trial.</i> J Clin Oncol 1987; 5: 1007-1014. [109]	21
IV.	GC Yee, SG Self, TR McGuire, J Carlin, JE Sanders, HJ Deeg <i>Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation.</i> N Engl J Med 1988; 319: 65-70. [83]	31
V.	RB Diasio, TL Beavers, JT Carpenter <i>Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity.</i> J Clin Invest 1988; 81: 47-51. [223]	39
VI.	AH Calvert, DR Newell, LA Gumbrell, S O'Reilly, M Burnell, FE Boxall, ZH Siddik, IR Judson, ME Gore, E Wiltshaw <i>Carboplatin dosage: Prospective evaluation of a simple formula based on renal function.</i> J Clin Oncol 1989; 7: 1748-1756. [842]	47
VII.	LB Grochow, RJ Jones, RB Brundrett, HG Braine, T-L Chen, R Saral, GW Santos, OM Colvin <i>Pharmacokinetics of busulfan: Correlation with veno-occlusive disease in patients undergoing bone marrow transplantation.</i> Cancer Chemother Pharmacol 1989; 25: 55-61. [176]	59

*The number in square brackets is the total number of citations for each article.

- VIII. L Lennard, JS Lilleyman, J Van Loon, RM Weinshilboum
Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia.
Lancet 1990; 336: 225-229. [290] 69
- IX. WE Evans, M Horner, YQ Chu, D Kalwinsky, WM Roberts
Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia.
J Pediatr 1991; 119: 985-989. [156] 77
- X. CF Stewart, SG Arbuck, RA Fleming, WE Evans
Relation of systemic exposure to unbound etoposide and hematologic toxicity.
Clin Pharmacol Ther 1991; 50: 385-393. [76] 85
- XI. DI Jodrell, MJ Egorin, RM Canetta, P Langenberg, EP Goldbloom, JN Burroughs, JL Goodlow, S Tan, E Wiltshaw
Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.
J Clin Oncol 1992; 10: 520-528. [205] 97
- XII. J-M Extra, F Rousseau, R Bruno, M Clavel, N Le Bail, M Marty
Phase I and pharmacokinetic study of taxotere (RP 56976; NSC 628503) given as a short intravenous infusion.
Cancer Res 1993; 53: 1037-1042. [131] 109
- XIII. V Gandhi, E Estey, MJ Keating, W Plunkett
Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.
J Clin Oncol 1993; 11: 116-124. [127] 117
- XIV. G Milano, MC Etienne, N Renée, A Thyss, M Schneider, A Ramaioli, F Demard
Relationship between fluorouracil systemic exposure and tumor response and patient survival.
J Clin Oncol 1994; 12: 1291-1295. [68] 129
- XV. TW Synold, MV Relling, JM Boyett, GK Rivera, JT Sandlund, H Mahmoud, WM Crist, C-H Pui, WE Evans
Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia.
J Clin Invest 1994; 94: 1996-2001. [98] 137
- XVI. DS Sonnichsen, CA Hurwitz, CB Pratt, JJ Shuster, MV Relling
Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors.
J Clin Oncol 1994; 12: 532-538. [74] 145
- XVII. L Gianni, CM Kearns, A Giani, G Capri, L Viganó, A Locatelli, G Bonadonna, MJ Egorin
Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.
J Clin Oncol 1995; 13: 180-190. [218] 155

- XVIII. CR Yates, EY Krynetski, T Loennechen, MY Fessing, H-L Tai, C-H Pui, MV Relling, WE Evans
Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance.
Ann Intern Med 1997; 126: 608-614. [158] 169
- XIX. JT Slattery, RA Clift, CD Buckner, J Radich, B Storer, WI Bensinger, E Soll, C Anasetti, R Bowden, E Bryant, T Chauncey, HJ Deeg, KC Doney, M Flowers, T Gooley, JA Hansen, PJ Martin, GB McDonald, R Nash, EW Petersdorf, JE Sanders, G Schoch, P Stewart, R Storb, KM Sullivan, ED Thomas, RP Witherspoon, FR Appelbaum
Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation.
Blood 1997; 89: 3055-3060. [75] 179
- XX. WE Evans, MV Relling, JH Rodman, WR Crom, JM Boyett, C-H Pui
Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia.
N Engl J Med 1998; 338: 499-505. [129] 187
- XXI. L Iyer, CD King, PF Whittington, MD Green, SK Roy, TR Tephly, BL Coffman, MJ Ratain
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.
J Clin Invest 1998; 101: 847-854. [103] 197
- XXII. MV Relling, ML Hancock, GK Rivera, JT Sandlund, RC Ribeiro, EY Krynetski, C-H Pui, WE Evans
Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.
J Natl Cancer Inst 1999; 91: 2001-2008. [71] 207